Keyphrases
Prostate Cancer
62%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
32%
Immune Checkpoint Blockade
31%
Neoadjuvant
31%
B7 Homolog 3
29%
T Cell Receptor
29%
Prostate-specific Antigen
23%
T Cells
23%
CD276
19%
Peptide-MHC Complex
18%
B7-H3
17%
Pan-cancer
14%
Racial Origin
14%
Clinical Characterization
14%
Immunomodulatory Response
14%
Plasmid DNA Vaccine
14%
Back to the Future
14%
Androgen Receptor
14%
Peptide Antigen
14%
Clinical Benefit
14%
Deep Learning
14%
T Cell Receptor-like Antibody
14%
Acute Promyelocytic Leukemia
14%
Androgen Deprivation Therapy
14%
Advanced Prostate Cancer
14%
Ct Value
14%
HLA-A2
14%
T Cell Antigen Recognition
14%
Oligometastatic Prostate Cancer
14%
Human Malignancies
14%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
14%
Immune Cells
14%
Transgenic Mice
14%
Small Bowel Carcinoid Tumor
14%
NY-ESO-1
14%
Extreme Response
14%
Phase II Trial
14%
Molecular Subtypes
14%
Localized Prostate Cancer
14%
Confinement Time
14%
Genomic Characterization
14%
Enzalutamide
14%
Morphological Characteristics
14%
PMHC
14%
T Cell Cross-reactivity
14%
Cross-reactivity
14%
18F-DCFPyL
14%
Therapeutic Target
14%
Tumor-specific Peptides
14%
Cell Density
14%
Medicine and Dentistry
Prostate Cancer
100%
Nivolumab
29%
DNA Mismatch Repair
25%
Prostate Specific Antigen
23%
Clinical Trial
20%
Androgen Receptor
19%
Immunocompetent Cell
17%
Gene Mutation
16%
Protein Expression
16%
Ipilimumab
14%
Clear Cell Renal Cell Carcinoma
14%
Fluorine-18
14%
Prostate Specific Membrane Antigen
14%
Acute Promyelocytic Leukemia
14%
Clinical Feature
14%
T Cell Receptor
14%
Cell Density
14%
Castration Resistant Prostate Cancer
14%
Carcinoid
14%
Positron Emission Tomography-Computed Tomography
14%
Enzalutamide
14%
Morphology
14%
T Lymphocyte
14%
Nectin
14%
Prostate Adenocarcinoma
14%
Machine Perfusion
14%
Graft Failure
14%
Xenotransplantation
14%
Heart Muscle Ischemia
14%
Ischemia
14%
T Cell
13%
Antigen Response
13%
Overall Survival
13%
Hormone Therapy
12%
Hazard Ratio
11%
Microsatellite Instability
11%
Immunotherapy
11%
Androgen Deprivation Therapy
10%
Neoplasm
9%
Immune Checkpoint Blockade
9%
Alkaline Phosphatase
8%
Nephrectomy
8%
Primary Tumor
8%
Immunohistochemistry
8%
Pembrolizumab
7%
Cryopreservation
7%
Interleukin-6
5%
Positron Emission Tomography
5%
Cytokine
5%
Polymerase Chain Reaction
5%
Immunology and Microbiology
Prostate
64%
T Cell
44%
T Cell Receptor
36%
Overall Survival
29%
Immunocompetent Cell
29%
Prostate Specific Antigen
23%
Mismatch Repair
17%
Transcriptomics
16%
Nivolumab
14%
Transgenic Mouse
14%
Exocytosis
14%
Protein Expression
14%
Ipilimumab
14%
CD276
14%
Cross-Reactivity
14%
Cell Density
14%
Enoblituzumab
14%
Xenotransplantation
14%
Cold Ischemia
14%
Perfusion
14%
Cytotoxic T-Cell
14%
Exome
12%
Macrophage
12%
Antigen Response
11%
Gene Mutation
10%
Lymphocyte
9%
Antigen Presentation
9%
Mouse
8%
Notch Signaling
7%
RNA Sequencing
7%
Immune Tolerance
7%
Wnt Signaling
7%
Surface Property
7%
Signal Transduction
7%
Epithelial Mesenchymal Transition
7%
Glycoprotein
7%
Immunotherapy
7%
Programmed Death-Ligand 1
7%
Cryopreservation
6%
Interleukin-6
5%
Progression Free Survival
5%
Failure Free Survival
5%
DNA Repair
5%
Cytokine
5%